Unilife, a designer, manufacturer and supplier of injectable drug delivery systems, announced the signing of a Global Strategic Alliance Agreement with Flextronics, a leading end-to-end supply chain solutions company, as its global strategic partner to further expand the production capacity and scale-up capability of Unilife's product portfolio.
The Global Strategic Alliance Agreement between Unilife and Flextronics will support accelerating commercial demand from a multitude of pharmaceutical customers who are seeking to leverage Unilife’s products and services to enhance and differentiate their injectable biologics, drugs and vaccines.
In addition to Unilife fully utilizing its own FDA-registered manufacturing facilities in York, Pennsylvania, Flextronics will serve as a secondary source of supply to Unilife and its pharmaceutical customers.
Dr. Ramin Mojdeh, President and Chief Operating Officer of Unilife, said: "This strategic alliance will further enhance our supply chain and maximize efficiencies by aligning our own production capacity and scale-up capability with Flextronics’ proven manufacturing expertise and established global size.
"Flextronics is a leading and trusted provider of supply chain solutions for the pharmaceutical industry, and has long-term relationships with many current and prospective Unilife customers."
"Flextronics is proud to collaborate and provide supply chain solutions to Unilife," said Mark Kemp, president of Flextronics Medical.
Unilife is a US based developer and commercial supplier of injectable drug delivery systems. Unilife’s portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems.